18.10.2022 - Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet .
Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Scopus BioPharma Inc (SCPS) Appoints Raphael Hofstein to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Company’s Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to.